AS 1405

Drug Profile

AS 1405

Alternative Names: AngioMab; AS1405; Monoclonal antibody BC1 Y 90; R 1405; Y90 mBC1; Yttrium 90 labelled monoclonal antibody BC1

Latest Information Update: 07 May 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Antisoma
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glioblastoma

Most Recent Events

  • 07 May 2005 Discontinued - Phase-I for Glioblastoma in United Kingdom (Parenteral)
  • 03 Mar 2005 AS 1405 is available for partnering (http://www.antisoma.com)
  • 04 May 2004 Phase-I clinical trials in Glioblastoma in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top